These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24745854)

  • 21. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.
    Wijnen PA; Op den Buijsch RA; Drent M; Kuijpers PM; Neef C; Bast A; Bekers O; Koek GH
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():211-9. PubMed ID: 18081664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
    Preskorn SH
    J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-induced interstitial lung disease: role of pharmacogenetics in predicting cytotoxic mechanisms and risks of side effects.
    Jessurun NT; Drent M; van Puijenbroek EP; Bekers O; Wijnen PA; Bast A
    Curr Opin Pulm Med; 2019 Sep; 25(5):468-477. PubMed ID: 31365381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacogenetic testing: soon before every prescription?].
    Buclin T; Colombo S; Biollaz J
    Rev Med Suisse; 2008 Jul; 4(165):1666-70. PubMed ID: 18767293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug interactions in dentistry: the importance of knowing your CYPs.
    Hersh EV; Moore PA
    J Am Dent Assoc; 2004 Mar; 135(3):298-311. PubMed ID: 15058617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future.
    Haas DM
    Obstet Gynecol Surv; 2013 Sep; 68(9):650-4. PubMed ID: 25102121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
    Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
    Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
.
    Sreter KB; Barisic B; Popovic-Grle S
    Int J Clin Pharmacol Ther; 2017 May; 55(5):442-448. PubMed ID: 28257284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome p450-mediated cardiovascular drug interactions.
    Cheng JW
    Heart Dis; 2000; 2(3):254-8. PubMed ID: 11728266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation.
    Duconge J; Ruaño G
    Pharmacogenomics; 2015; 16(15):1685-8. PubMed ID: 26431456
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.
    Tanaka E
    J Clin Pharm Ther; 1998 Dec; 23(6):403-16. PubMed ID: 10048501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
    Krau SD
    Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics and systems biology of membrane transporters.
    Yan Q
    Mol Biotechnol; 2005 Jan; 29(1):75-88. PubMed ID: 15668521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-drug-gene interactions and adverse drug reactions.
    Malki MA; Pearson ER
    Pharmacogenomics J; 2020 Jun; 20(3):355-366. PubMed ID: 31792369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?
    Stillemans G; Belkhir L; Hesselink DA; Haufroid V; Elens L
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):601-611. PubMed ID: 29775551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.
    Fermier N; Bourguignon L; Goutelle S; Bleyzac N; Tod M
    Clin Pharmacokinet; 2018 Dec; 57(12):1581-1591. PubMed ID: 29572664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges in pharmacotherapy for older adults: a framework for pharmacogenomics implementation.
    Roman YM; Dixon DL; Salgado TM; Price ET; Zimmerman KM; Sargent L; Slattum PW
    Pharmacogenomics; 2020 Jun; 21(9):627-635. PubMed ID: 32425117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytochrome P450 enzyme isoforms and their therapeutic implications: an update.
    Kalra BS
    Indian J Med Sci; 2007 Feb; 61(2):102-16. PubMed ID: 17259690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.